KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.